


Product Name : NX-2127
Cat. No. : PC-20560
CAS No. : 2416131-46-7
Molecular Formula : C₃₉H₄₅N₉O₅
Molecular Weight : 719.85
Target : PROTAC
Solubility : 10 mM in DMSO



CAS: 2416131-46-7

Biological Activity

NX-2127 (NX2127) is a hetero-bifunctional, orally active **PROTAC** that induces the degradation of **BTK** and IKZF3 ubiquitination and proteasomal degradation in cells through recruitment of cereblon (CRBN).

NX-2127 degrades BTK in multiple B cell lymphoma lines with DC50 values in the range of 1-13 nM.

NX-2127 displays efficient cellular degradation yet binds to WT and mutant BTK with affinities that render covalent and noncovalent BTK inhibitors ineffective.

NX-2127 drives cellular ternary complex formation between BTK and CRBN by inducing positive cooperativity in both WT and acquired resistance mutant settings.

NX-2127 induces potent degradation of C481S, T474I, V416L, and L528W-mutant BTK and suppresses activation marker expression on cells harboring these mutations.

NX-2127 demonstrates oral bioavailability across pre-clinical species and shows robust tumor growth inhibition in WT and mutant mouse models of lymphoma upon once daily PO dosing.

References

Jeffrey T. Mihalic, et al. *Cancer Res* (2023) 83 (7_Supplement): 3423.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com